Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.
Hudis C, et al. Among authors: baselga j.
J Clin Oncol. 1999 Jan;17(1):93-100. doi: 10.1200/JCO.1999.17.1.93.
J Clin Oncol. 1999.
PMID: 10458222
Clinical Trial.